| Literature DB >> 28235364 |
Olena S Kukolevska1,2, Igor I Gerashchenko3, Mykola V Borysenko3, Evgenii M Pakhlov3, Michal Machovsky4, Tetyana I Yushchenko5.
Abstract
Preparation of poly(2-hydroxyethyl methacrylate) (PHEMA) based nanocomposites using different approaches such as synthesis with water as the porogen, filling of polymer matrix by silica and formation of interpenetrating polymer networks with polyurethane was demonstrated. Incorporation of various biologically active compounds (BAC) such as metronidazole, decamethoxin, zinc sulphate, silver nitrate or amino acids glycine and tryptophan into nanocomposites was achieved. BAC were introduced into the polymer matrix either (1) directly, or (2) with a solution of colloidal silica, or (3) through immobilization on silica (sol-densil). Morphology of prepared materials was investigated by laser scanning microscopy and low-vacuum scanning electron microscopy. In vacuum freeze-drying, prior imaging was proposed for improving visualization of the porous structure of composites. The interaction between PHEMA matrix and silica filler was investigated by IR spectroscopy. Adsorption of 2-hydroxyethyl methacrylate and BAC from aqueous solution on the silica surface was also examined. Phase composition and thermal stability of composites were studied by the differential thermogravimetry/differential thermal analysis. Release of BAC into water medium from prepared composites were shown to depend on the synthetic method and differed significantly. Obtained PHEMA-base materials which are characterized by controlled release of BAC have a strong potential for application in manufacturing of different surgical devices like implants, catheters and drainages.Entities:
Keywords: Biologically active compounds; Controlled release; Nanocomposites; Poly(2-hydroxyethyl methacrylate); Pore formation; Silica
Year: 2017 PMID: 28235364 PMCID: PMC5318307 DOI: 10.1186/s11671-017-1881-7
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Composition of the studied materials
| No of series | Polymer matrix | Introduced into the matrix |
|---|---|---|
| 1 | PHEMA | BAC (see Table |
| 2 | PHEMA | 10 or 15% of sol-densil |
| 3 | PHEMA/water | BAC |
| 4 | PHEMA/water | 10 or 15% of sol-densil |
| 5 | PHEMA/water | 10 or 15% of nanosilica + BAC |
| 6 | PU | 10 or 15% of sol-densil |
| 7 | IPN 83%PU/17%PHEMA | 10 or 15% of sol-densil |
| 8 | PU | – |
| 9 | IPN 83%PU/17%PHEMA | – |
| 10 | PHEMA | – |
| 11 | PHEMA | 5% of nanosilica |
| 12 | PHEMA/water | – |
| 13 | PHEMA/water | 10, 20, 30 or 40% of nanosilica |
BAC which were included into nanocomposites
| Compound, manufacturer | wt% |
|---|---|
| Metronidazole (China) | 3.6 |
| Decamethoxin (“Pharmhim”, Ukraine) | 2.9 |
| ZnSO4 × 7H2O (Russia) | 2.2 |
| AgNO3 (“Macrokhim”, Ukraine) | 1.3 |
| Glycine (China) | 2.2 |
| Tryptophan (China) | 2.9 |
Fig. 1LSM samples: PHEMA (No 10)—dry (a) and swollen (b); IPN PU/PHEMA (No 9)—dry (c) and swollen (d); and PU (No 8)—dry (e) and swollen (f). Methylene blue solution is used in the samples (b) and (d) for the image contrast
Fig. 2LVSEM of samples after freeze-drying: PHEMA (No 10) (a); PHEMA/5% nanosilica (No 11) (b); PHEMA synthesized in the presence of water (No 12) (c) and PHEMA synthesized with water/10% nanosilica (No 13) (d)
Fig. 3Nitrogen adsorption/desorption isotherm for freeze-drying PHEMA sample synthesized with porogen (No 12)
Fig. 4IR spectra of PHEMA/nanosilica composites (series No 13)
Fig. 5Adsorption isotherm of HEMA on the nanosilica surface from aqueous medium
Effect of HEMA on BAC adsorption (A, mmol/g) on nanosilica surface
| The initial content of BAC in the solution, milligrams per milliliter | Decamethoxin | AgNO3 | Metronidazole | ZnSO4 | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| 0.2–12.5 | 3 | 2.8 | 2.6 | 1.7 | 0.8 | 0.5 | 0.4 | 0.1 |
| 0.4–25 | 6.2 | 6.1 | 3.1 | 1.7 | 1.1 | 1 | 0.8 | 0.7 |
a A HEMA—adsorption of BAC in the presence of solution of HEMA
Fig. 6BAC release kinetics from nanocomposites: a) metronidazole, b) decamethoxin, c) Zn2+, d) Ag+, e) glycine and f) tryptophan. Curve numbers correspond to the samples in Table 1
BAC maximal release (in %) from the samples
| BAC or ion | Series numbers according to Table | ||||||
|---|---|---|---|---|---|---|---|
| No 1 | No 2a | No 3 | No 4 | No 5 | No 6 | No 7 | |
| Metronidazole | 96 | 10 | 92 | 42 | 89 | 42 | 31 |
| Decamethoxin | 57 | 1 | 44 | 40 | 41 | 16 | 6 |
| Zn2+ | 3 | 0 | 66 | 75 | 92 | 98 | 86 |
| Ag+ | 95 | 8 | 74 | 71 | 72 | 31 | 52 |
| Glycine | 42 | 4 | 100 | 52 | 92 | 79 | 73 |
| Tryptophan | 92 | 7 | 77 | 63 | 67 | 0 | 0 |
aAccording TGA, a small amount of sol-densil went into samples of this series (poor preparation technology)
Fig. 7DTG curves of samples based on various polymer matrices with a filler (a) and without it (b)